Vicki Krause
Vicki Krause has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alyson Wright
Australian National University Research School of Population Health
1 shared publication - Bart J. Currie
Global and Tropical Health Division, Menzies School of Health Research, Charles Darwin University
1 shared publication - Christina Barry
Vaccine Preventable Diseases Surveillance Section, Office of Health Protection, Department of Health and Ageing, Canberra, Australian Capital Territory
1 shared publication Francis J Bowden
Disease Control, Northern Territory Department of Health and Community ServicesGPO Box 40596DarwinNT0811
1 shared publicationHeather M Cook
Centre for Disease Control, Department of Health, Casuarina, Northern Territory
1 shared publication- Johanna Marie Birrell
Northern Territory Centre for Disease Control, NT Health Darwin NT
1 shared publication
Latest Publications
- Open Access
- 29 July 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 135, 125-131
Non-tuberculous mycobacterial skin and soft tissue infections in the Northern Territory, Australia, 1989-2021
- 29 July 2023
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 135, 125-131
Open AccessNon-tuberculous mycobacterial skin and soft tissue infections in the Northern Territory, Australia, 1989-2021
- Open Access
- 2 October 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 101 (4) , 753-760
Characteristics and Impact of Disseminated Gonococcal Infection in the “Top End” of Australia
The “Top End” of Australia is presently experiencing a gonorrhea epidemic. Gonococcal infection is usually limited to mucosal tissues but can lead to disseminated gonococcal infection (DGI), joint destruction, and severe sepsis. This study aimed to explore the epidemiology, presentation, management, and health-care impact of DGI in the Top End of the Northern Territory. Health records of patients diagnosed with proven, probable, or possible DGI between January 2010 and September 2018 were analyzed retrospectively. One hundred six cases of DGI were identified. Ninety-four patients (88.7%) were Indigenous Australian. The incidence of proven and probable DGI in the Indigenous population was 27.1 per 100,000 person-years, compared with 7.1 in the Top End population overall. Of 7,540 laboratory-proven gonococcal notifications, 1.3% (n = 97) were complicated by DGI. The highest incidence was in the 15–19-year age-group. Thirteen cases (12.3%) occurred in patients younger than 15 years. High rates of comorbid alcohol misuse, diabetes, systemic lupus erythematosus, rheumatic fever, and complement deficiency were observed. The “classic triad” of tenosynovitis, dermatitis, and polyarthralgia was rare. Ninety-four patients (88.7%) presented with purulent arthritis. Disseminated gonococcal infection was estimated to cause at least 10.0% of nonpenetrating septic arthritis in the Top End and 1,234 days of hospitalization during the study period. DGI is an important cause of morbidity in the Top End, particularly in the young, remote Indigenous Australian population. Clinical presentation varies from classical teaching. Urgent action in the health and community sector is required, particularly for at-risk populations, to prevent further debilitating and costly complications of gonococcal infection.
- 2 October 2019
- Published by American Society of Tropical Medicine and Hygiene in The American Journal of Tropical Medicine and Hygiene
- Vol. 101 (4) , 753-760
Open AccessCharacteristics and Impact of Disseminated Gonococcal Infection in the “Top End” of Australia
The “Top End” of Australia is presently experiencing a gonorrhea epidemic. Gonococcal infection is usually limited to mucosal tissues but can lead to disseminated gonococcal infection (DGI), joint destruction, and severe sepsis. This study aimed to explore the epidemiology, presentation, management, and health-care impact of DGI in the Top End of the Northern Territory. Health records of patients diagnosed with proven, probable, or possible DGI between January 2010 and September 2018 were analyzed retrospectively. One hundred six cases of DGI were identified. Ninety-four patients (88.7%) were Indigenous Australian. The incidence of proven and probable DGI in the Indigenous population was 27.1 per 100,000 person-years, compared with 7.1 in the Top End population overall. Of 7,540 laboratory-proven gonococcal notifications, 1.3% (n = 97) were complicated by DGI. The highest incidence was in the 15–19-year age-group. Thirteen cases (12.3%) occurred in patients younger than 15 years. High rates of comorbid alcohol misuse, diabetes, systemic lupus erythematosus, rheumatic fever, and complement deficiency were observed. The “classic triad” of tenosynovitis, dermatitis, and polyarthralgia was rare. Ninety-four patients (88.7%) presented with purulent arthritis. Disseminated gonococcal infection was estimated to cause at least 10.0% of nonpenetrating septic arthritis in the Top End and 1,234 days of hospitalization during the study period. DGI is an important cause of morbidity in the Top End, particularly in the young, remote Indigenous Australian population. Clinical presentation varies from classical teaching. Urgent action in the health and community sector is required, particularly for at-risk populations, to prevent further debilitating and costly complications of gonococcal infection.
- Open Access
- 1 June 2012
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 36 (2) , 151-165
Invasive pneumococcal disease in Australia 2007 and 2008
Errata published in CDI vol. 36 no. 4 (December 2012). The data in Figure 4 was a repeat of that in Figure 5, and the correct data for Figure 4 was not published The correct Figure is displayed in the attached Errata document. Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2007 and 2008 with comprehensive comparative data available since 2002. There were 1,477 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2007; a notification rate of 7.0 cases per 100,000 population. In 2008 there were 1,628 cases; a notification rate of 7.6 cases per 100,000 population. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in 2007 and almost 5 times in 2008. By 2008, the 4th year of a funded universal infant 7-valent pneumococcal conjugate vaccine (7vPCV) program in Australia with a 3+0 schedule, vaccine serotype IPD notification rates in those identified as non-Indigenous decreased in all age groups compared with 2002 levels, most significantly by 96% in children aged less than 5 years. However, rates of disease in non-vaccine serotypes increased by 168% in children aged less than 5 years, including a four-fold increase in the number of cases due to serotype 19A. For the Aboriginal and Torres Strait Islander population, national pre-vaccination data are not available, as the vaccine program was funded for this group from 2001. From 2002 to 2008, the proportion of disease due to 7vPCV serotypes in children aged less than 5 years decreased by 77%, while disease due to non-7vPCV serotypes increased by 76%. In Indigenous adults (≥50 years), rates of 23vPPV serotypes increased by 92%. There were 120 deaths attributed to IPD in 2007 and 113 in 2008, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remains low and reduced susceptibility to third-generation cephalosporins is rare. Commun Dis Intell 2012;36(2):E151–E165.
- 1 June 2012
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 36 (2) , 151-165
Open AccessInvasive pneumococcal disease in Australia 2007 and 2008
Errata published in CDI vol. 36 no. 4 (December 2012). The data in Figure 4 was a repeat of that in Figure 5, and the correct data for Figure 4 was not published The correct Figure is displayed in the attached Errata document. Enhanced surveillance for invasive pneumococcal disease (IPD) was conducted in all Australian states and territories in 2007 and 2008 with comprehensive comparative data available since 2002. There were 1,477 cases of IPD notified to the National Notifiable Diseases Surveillance System in Australia in 2007; a notification rate of 7.0 cases per 100,000 population. In 2008 there were 1,628 cases; a notification rate of 7.6 cases per 100,000 population. The overall rate of IPD in Indigenous Australians was almost 6 times the rate in non-Indigenous Australians in 2007 and almost 5 times in 2008. By 2008, the 4th year of a funded universal infant 7-valent pneumococcal conjugate vaccine (7vPCV) program in Australia with a 3+0 schedule, vaccine serotype IPD notification rates in those identified as non-Indigenous decreased in all age groups compared with 2002 levels, most significantly by 96% in children aged less than 5 years. However, rates of disease in non-vaccine serotypes increased by 168% in children aged less than 5 years, including a four-fold increase in the number of cases due to serotype 19A. For the Aboriginal and Torres Strait Islander population, national pre-vaccination data are not available, as the vaccine program was funded for this group from 2001. From 2002 to 2008, the proportion of disease due to 7vPCV serotypes in children aged less than 5 years decreased by 77%, while disease due to non-7vPCV serotypes increased by 76%. In Indigenous adults (≥50 years), rates of 23vPPV serotypes increased by 92%. There were 120 deaths attributed to IPD in 2007 and 113 in 2008, although it should be noted that deaths may be under-reported. The number of invasive pneumococcal isolates with reduced penicillin susceptibility remains low and reduced susceptibility to third-generation cephalosporins is rare. Commun Dis Intell 2012;36(2):E151–E165.
- 4 February 2008
- Published by AMPCo in Medical Journal of Australia
- Vol. 188 (3) , 144-147
Tuberculosis in illegal foreign fishermen: whose public health are we protecting?
Objective: To document demographic details, prevalence of tuberculosis (TB), and completion of TB treatment in illegal foreign fishermen detained in Australia. Design and participants: Clinical audit...
- 4 February 2008
- Published by AMPCo in Medical Journal of Australia
- Vol. 188 (3) , 144-147
Tuberculosis in illegal foreign fishermen: whose public health are we protecting?
Objective: To document demographic details, prevalence of tuberculosis (TB), and completion of TB treatment in illegal foreign fishermen detained in Australia. Design and participants: Clinical audit...
- 1 September 1994
- Published by AMPCo in Medical Journal of Australia
- Vol. 161 (6) , 372-373
Should Aboriginals in the “Top End” of the Northern Territory be vaccinated against hepatitis A?
Objective To determine the level of immunity to hepatitis A virus infection in rural Australian Aboriginal populations in the “Top End” of the Northern Territory. Methods A total of 344 sera, for which details of donors' age, sex and domicile were available, were collected and tested for hepatitis A total antibody in a delinked sero‐prevalence study. Results Overall, 337/344 samples (97.97%) tested positive for hepatitis A total antibodies —18/20 samples (90%) in the 1‐5 year age group; 85/88 (96.6%) in the 6‐10 year age group; 98/98 (100%) in the 11‐15 year age group; 32/33 (97.0%) in the 16‐20 year age group and 104/105 (99%) in the older than 20 year age group. Conclusion Hepatitis A is hyperendemic in the rural Aboriginal communities studied and the virus is acquired predominantly in the first five years of life. Symptomatic hepatitis A infection is uncommon in this population. We suggest that hepatitis A vaccination for rural Aboriginal children is not indicated as it would not reduce clinical disease rates and may produce a cohort whose immunity could decrease over the following 10 years. Although vaccination is appropriate for non‐immune individuals working in remote communities, emphasis must be placed on the inequities in health infrastructure and education underlying the high transmission rates in Aboriginal children.
- 1 September 1994
- Published by AMPCo in Medical Journal of Australia
- Vol. 161 (6) , 372-373
Should Aboriginals in the “Top End” of the Northern Territory be vaccinated against hepatitis A?
Objective To determine the level of immunity to hepatitis A virus infection in rural Australian Aboriginal populations in the “Top End” of the Northern Territory. Methods A total of 344 sera, for which details of donors' age, sex and domicile were available, were collected and tested for hepatitis A total antibody in a delinked sero‐prevalence study. Results Overall, 337/344 samples (97.97%) tested positive for hepatitis A total antibodies —18/20 samples (90%) in the 1‐5 year age group; 85/88 (96.6%) in the 6‐10 year age group; 98/98 (100%) in the 11‐15 year age group; 32/33 (97.0%) in the 16‐20 year age group and 104/105 (99%) in the older than 20 year age group. Conclusion Hepatitis A is hyperendemic in the rural Aboriginal communities studied and the virus is acquired predominantly in the first five years of life. Symptomatic hepatitis A infection is uncommon in this population. We suggest that hepatitis A vaccination for rural Aboriginal children is not indicated as it would not reduce clinical disease rates and may produce a cohort whose immunity could decrease over the following 10 years. Although vaccination is appropriate for non‐immune individuals working in remote communities, emphasis must be placed on the inequities in health infrastructure and education underlying the high transmission rates in Aboriginal children.